Search research articles

Search research articles

Related Experiment Videos

The newer fluoroquinolones.

Judith A O'Donnell¹, Steven P Gelone

¹Division of Infectious Diseases, Drexel University, College of Medicine, Medical College of PA Hospital, 3300 Henry Avenue, Philadelphia, PA 19129, USA. jao25@drexel.com

Infectious Disease Clinics of North America

|August 17, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development and Validation of Case-Finding Algorithms to Identify Periprosthetic Joint Infections After Total Hip Arthroplasty in Veterans Health Administration Data.

Pharmacoepidemiology and drug safety·2026

Same author

Respiratory equality: let's stop playing favorites with COVID-19 in the healthcare setting.

Infection control and hospital epidemiology·2024

Same author

Chlamydial Proctitis.

The New England journal of medicine·2024

Same author

In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice.

International journal of molecular sciences·2024

Same author

Physiologically-based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients.

CPT: pharmacometrics & systems pharmacology·2024

Same author

Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.

Clinical therapeutics·2024

Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026

Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026

Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026

Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026

Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026

Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Newer fluoroquinolones offer improved pharmacokinetics and broader activity for respiratory, skin, and genitourinary infections. This review details their efficacy, safety, and appropriate clinical use compared to older agents.

Area of Science:

Pharmacology
Infectious Diseases
Microbiology

Background:

Fluoroquinolones are a class of synthetic broad-spectrum antibacterial drugs.
Older fluoroquinolones, such as ciprofloxacin, have established roles in treating various infections.
Emerging fluoroquinolone agents present opportunities for enhanced therapeutic options.

Purpose of the Study:

To provide a comprehensive review of newer fluoroquinolone agents.
To compare their pharmacokinetic and pharmacodynamic profiles with older fluoroquinolones.
To evaluate their in vitro activity, safety, and clinical efficacy across diverse infections.

Main Methods:

Literature review of pharmacokinetic, pharmacodynamic, and clinical studies.
Comparative analysis of newer versus older fluoroquinolones, including ciprofloxacin.

Related Experiment Videos

Examination of in vitro susceptibility data and clinical trial outcomes.

Main Results:

Newer fluoroquinolones exhibit distinct pharmacokinetic and pharmacodynamic properties.
They demonstrate a broad spectrum of in vitro activity against common pathogens.
Clinical data support their efficacy in respiratory, skin, genitourinary, and gastrointestinal infections.

Conclusions:

Newer fluoroquinolones represent valuable additions to the antimicrobial armamentarium.
Their appropriate use is crucial for optimizing treatment outcomes and managing resistance.
Further research should focus on long-term safety and specific indications.